Restoring Dystrophin via Exon Skipping Strategies AOC 1044 – Mark Stahl, MD (Avidity Biosciences) BMN 351 – Dave Jacoby MD, PhD (BioMarin Pharmaceutical Inc.) DYNE-251 – Ash Dugar, PhD, MBA (Dyne Therapeutics) ED051 – Michelle Mellion, MD (PepGen, Inc.) ENTR-601-44 – Nerissa Kreher, MD, MBA (Entrada Therapeutics) SRP-5051 – Teji Singh, MD (Sarepta Therapeutics) WVE-N531 – Mike Panzara, MD, MPH (Wave Life Sciences) 4 years ago 2022 PPMD Annual Conference,Conferences & Meetings You may also like 11:20 PTC Therapeutics (Ataluren) 6 years ago Conferences & Meetings,In the Pipeline: Restoring Dystrophin 15:10 Daiichi-Sankyo 6 years ago Conferences & Meetings,In the Pipeline: Restoring Dystrophin 20:43 ReveraGen BioPharma 6 years ago Conferences & Meetings,In the Pipeline: Reducing Inflammation 12:20 Catabasis 6 years ago Conferences & Meetings,In the Pipeline: Reducing Inflammation 11:23 Antisense Therapeutics 6 years ago Conferences & Meetings,In the Pipeline: Reducing Inflammation 13:19 PTC Therapeutics 6 years ago Approved Therapies,Conferences & Meetings 15:43 Sarepta Therapeutics 6 years ago Approved Therapies,Conferences & Meetings 7:48 What is a Post Market Study? 6 years ago Approved Therapies,Conferences & Meetings «1…2223242526…28»Page 24 of 28